Deciphering the hierarchy of angiohematopoietic progenitors from human pluripotent stem cells

Igor I. Slukvin
Department of Pathology and Laboratory Medicine; School of Medicine and Public Health; University of Wisconsin; Madison, WI USA;
Department of Cell and Regenerative Medicine; School of Medicine and Public Health; University of Wisconsin; Madison, WI USA;
National Primate Research Center; University of Wisconsin Graduate School; Madison, WI USA

Identification of sequential progenitors leading to blood formation from pluripotent stem cells (PSCs) will be essential for understanding the molecular mechanisms of hematopoietic lineage specification and for development of technologies for in vitro production of hematopoietic stem cells (HSCs). It is well established that during development, blood and endothelial cells in the extraembryonic and embryonic compartments are formed in parallel from precursors with angiogenic and hematopoietic potentials. However, the identity and hierarchy of these precursors in human PSC (hPSC) cultures remain obscure. Using developmental stage-specific mesodermal and endothelial markers and functional assays, we recently identified discrete populations of angiohematopoietic progenitors from hPSCs, including mesodermal precursors and hemogenic endothelial cells with primitive and definitive hematopoietic potentials. In addition, we discovered a novel population of multipotent hematopoietic progenitors with an erythroid phenotype, which retain angiogenic potential. Here we introduce our recent findings and discuss their implication for defining putative HSC precursor and factors required for activation of self-renewal potential in hematopoietic cells emerging from endothelium.

Introduction

The discovery of human pluripotent stem cells (hPSCs), both embryonic (ESCs) and induced (iPSCs), have opened novel opportunities to model human diseases, screen drugs and manufacture cells for transplantation therapy in vitro. ESCs and iPSCs can be propagated almost indefinitely in culture and differentiated into any cell type in the human body. The pattern of differentiation from ESCs and iPSCs toward particular cell lineage is very similar. Recently, significant progress has been made in differentiating PSCs toward hematopoietic progenitors and diverse types of blood cells. However, the generation of hematopoietic stem cells (HSCs) with bone marrow reconstitution potential from PSCs remains a significant challenge. The identification of immediate blood precursors and mechanisms guiding specification and diversification of hematopoietic cells from PSCs is essential for overcoming this major limitation of current PSC differentiation systems.

During embryogenesis, the first hematopoietic cells are generated in parallel with endothelial cells in the yolk sac. The close spatial and temporal relationship between blood and endothelial cells was noted by early embryologists in the late 19th century. In 1917, Florence Sabin postulated the existence of a bipotential precursor for blood and endothelial cells based on her observations of blood development within the yolk sac in chicken embryos. This bipotential precursor was later named hemangioblast by Murray. At embryonic day 7.5 (E7.5), the mouse yolk sac initially gives rise to primitive hematopoietic cells, including nucleated erythrocytes, macrophages and megakaryocytes. The primitive hematopoiesis is
eventually supplanted by definitive hematopoiesis that give rise to HSCs with the potential to reconstitute the wild type adult mice. The first definitive HSCs are detected in the aorta-gonad-mesonephros (AGM) region at E10.5.\textsuperscript{15} In this region, HSCs arise from endothelial cells with blood-forming potential or hemogenic endothelium (HE).\textsuperscript{15-20} The budding of blood-forming potential or hemogenic (AGM) region at E10.5. \textsuperscript{15} In this region, detected in the aorta-gonad-mesonephros adult mice. The first definitive HSCs are potential to reconstitute the wild type eventually supplanted by definitive hematopoietic potential underscores that HSCs originate from HE with definitive hematopoietic potential. \textsuperscript{31,37,39} The core stage of differentiation is readily identifiable after 3 d of culture of PM cells in clonogenic medium. Subsequently, VE-cadherin core-forming cells transform into blood cells with VE-cadherin-CD235a\textsuperscript{+/-}CD41a\textsuperscript{-} phenotype and erythroblast morphology. BL-CFC hematopoiesis is mostly restricted to erythroid cells producing embryonic e- but no adult \(\beta\)-hemoglobin, megakaryocytes, and macrophages, indicating that in response to FGF2, PM cells generate an endothelial intermediate that undergoes transition into definitive hematopoietic cells. Although PM cells generate mostly primitive blood cells in serum-free semisolid medium in response to FGF2, further culture of these cells on OP9 produces cells with definitive hematopoietic potential.

The next, more advanced stage of hematopoietic commitment toward hematopoietic cells is associated with emergence of hematovascular mesodermal precursors (HVMPs), which can be discriminated at day 3.5 of differentiation based on increased KDR and decreased PDGFR\(\alpha\) expression by APLNR\textsuperscript{+} cells (see Fig. 1 and Table 1).\textsuperscript{37} The emerging KDR\textsuperscript{high}APLNRPDGFR\(\alpha\)HVMPs have large blast morphology and remain EMHlin\textsuperscript{-}, i.e., do not express VE-cadherin, CD31, CD105, CD73, CD43 or CD45. Similar to PM, the HVMPs express genes associated with lateral plate/extraembryonic mesoderm. However, they downregulate primitive streak genes and upregulate \(TAL1, HHX, LMO2, GATA2\) and \(ETV2\), genes associated with angiohematopoietic development (Figs. 1 and 2A). Functional analysis revealed that HVMPs lost FGF2-dependent BL colony-forming potential. However, single cell deposition assay demonstrated that this population was highly enriched in cells capable of forming hematoidoendothelial clusters on OP9 (Fig. 2C). Dynamic imaging studies of hematoidoendothelial clusters revealed that endothelial cells within these clusters gradually acquired hematopoietic morphology and phenotype, i.e., underwent endothelial-to-hematopoietic transition.\textsuperscript{37}VE-cadherin is considered one of the earliest markers of endothelial-lineage cells in the embryo.\textsuperscript{40,41} In hPSC co-cultures with OP9, the first VE-cadherin\textsuperscript{+} cells arise from HVMPs by day 4 of differentiation.\textsuperscript{37} The expression of VE-cadherin coincided with upregulation of the endothelial markers CD31 (PECAM) and ESAM and other typical endothelial genes including \(PROC, SCARFI, ECSR\) and \(NOS3\), signifying the endothelial commitment following acquisition of VE-cadherin expression by cells arising from HVMPs. Although emerging VE-cadherin\textsuperscript{+} cells were homogenous in expression of CD31, ESAM and other typical endothelial markers such as TEK, KDR, CD34, CD141, CD146 and CD201, we were able to discriminate the following distinct subsets within this population based on expression of the endothelial/mesenchymal marker CD73 (5\textsuperscript{-}nucleotidase) and the hematopoietic markers, CD235a and CD43 (Glycophorin A

Identification of Hierarchy of Angiohematopoietic Progenitors in Human PSC Differentiation Cultures

To induce hematopoietic differentiation, we co-cultured hPSCs on OP9 mouse stromal cells.\textsuperscript{25,30} Co-culture of PSCs on OP9 induces their differentiation toward mesoderm and endoderm with no detectable ectoderm.\textsuperscript{31} To define the distinct stages of mesodermal commitment, we analyzed the expression of the typical mesodermal markers APLNR,\textsuperscript{31-33} KDR\textsuperscript{34} and PDGFR\(\alpha\) (CD140a)\textsuperscript{35} on differentiated hPSCs before endodermal, mesenchymal and hematopoietic lineage-commitment markers became detectable. We found that differentiated PSCs upregulate APLNR after 2 d of co-culture on OP9. During days 2–3 of differentiation, APLNR\textsuperscript{+} cells upregulate PDGFR\(\alpha\), KDR and genes associated with primitive streak and lateral plate/extraembryonic mesoderm,\textsuperscript{36} but lack endothelial (CD31, VE-cadherin), endothelial/mesenchymal stem cell (CD73, CD105) and hematopoietic (CD43, CD45) lineage-specific markers (Fig. 1 and Table 1), hereafter referred to as EMHlin\textsuperscript{-}. In the OP9 co-culture, the day 3 EMHlin\textsuperscript{-}APLNRPDGFR\(\alpha\) mesodermal cells represent a transient population of mesoderm reminiscent of the primitive posterior mesoderm (PM) in the embryo with the potential to form blast (BL) or hemangioblast (HB) colonies in response to FGF2.\textsuperscript{31,37} The BL colony-forming cells (BL-CFCs) reflect the first wave of hematopoiesis in PSC cultures.\textsuperscript{31,37,38} The development of BL colonies in clonogenic cultures proceed through a core stage at which PM cells form clusters of tightly-packed cells (cores) composed of VE-cadherin\textsuperscript{+} cells with epithelioid morphology, endothelial gene expression profile and endothelial potential.\textsuperscript{31,37,39} The core stage of differentiation is readily identifiable after 3 d of culture of PM cells in semi-solid clonogenic medium. Subsequently, VE-cadherin core-forming cells transform into blood cells with VE-cadherin-CD235a\textsuperscript{+/-}CD41a\textsuperscript{-} phenotype and erythroblast morphology. BL-CFC hematopoiesis is mostly restricted to erythroid cells producing embryonic e- but no adult \(\beta\)-hemoglobin, megakaryocytes, and macrophages, indicating that in response to FGF2, PM cells generate an endothelial intermediate that undergoes transition into definitive hematopoietic cells. Although PM cells generate mostly primitive blood cells in serum-free semisolid medium in response to FGF2, further culture of these cells on OP9 produces cells with definitive hematopoietic potential.
lacked CD226 expression but expressed CD117 at a very high level. In vivo studies demonstrated that expression of \textit{Runx1} distinguishes hemogenic and non-hemogenic endothelium within mouse AGM.\textsuperscript{44} Similarly, HEPs isolated from hPSCs had a much higher expression of \textit{RUNX1} compared with non-HEPs (Fig. 2B).

Previously we demonstrated that expression of CD43 (leukosialin) during PSC differentiation defines hematopoietic progenitors with colony-forming potential, detectable using standard serum-containing semisolid medium supplemented with hematopoietic cytokines.\textsuperscript{36} Expression of CD43 reliably separates hematopoietic progenitors from CD43\textsuperscript{−}CD31\textsuperscript{+} endothelial cells and CD43\textsuperscript{−}CD31\textsuperscript{−} mesenchymal cells. Although all of these subsets were capable of generating endothelial cells after culture on fibronectin in endothelial media, analysis of their hematopoietic and endothelial potentials using hematopoietic CFC assay and secondary co-culture with OP9 revealed that these newly identified VE-cadherin\textsuperscript{−} subsets have distinct functional properties. Freshly isolated VE-cadherin\textsuperscript{−}CD73\textsuperscript{−}CD235a/CD43\textsuperscript{−} cells did not form colonies in hematopoietic CFC medium but were capable of generating endothelial cells and lin\textsuperscript{−}CD34\textsuperscript{−}CD45\textsuperscript{−}CD38\textsuperscript{−} multipotent definitive hematopoietic progenitors after co-culture with OP9. Based on these findings, we designated these cells as hemogenic endothelial progenitors (HEPs). Because VE-cadherin\textsuperscript{+}CD73\textsuperscript{+}CD235a/CD43\textsuperscript{+} formed endothelial colonies but not hematopoietic cells after secondary culture with OP9, we designated these cells as non-HEPs. Molecular profiling and analysis of surface marker expression revealed that HEPs and non-HEPs could be also discriminated based on expression of CD226 and CD117 (c-kit). CD73\textsuperscript{−}HEPs expressed CD226 or DNAM-1, a cell surface marker typically found on hematopoietic cells (NK and T cells, myeloid and megakaryocytic cells). They also expressed CD117 at an intermediate level.\textsuperscript{42,43} In contrast, CD73\textsuperscript{+} non-HEPs lacked CD226 expression but expressed CD117 at a very high level. In vivo studies demonstrated that expression of \textit{Runx1} distinguishes hemogenic and non-hemogenic endothelium within mouse AGM.\textsuperscript{44} Similarly, HEPs isolated from hPSCs had a much higher expression of \textit{RUNX1} as compared with non-HEPs (Fig. 2B).

Previously we demonstrated that expression of CD43 (leukosialin) during PSC differentiation defines hematopoietic progenitors with colony-forming potential, detectable using standard serum-containing semisolid medium supplemented with hematopoietic cytokines.\textsuperscript{36} Expression of CD43 reliably separates hematopoietic progenitors from CD43\textsuperscript{−}CD31\textsuperscript{+} endothelial cells and CD43\textsuperscript{−}CD31\textsuperscript{−} mesenchymal
and mixed colonies, indicating that they are multipotent hematopoietic cells, which include CFCs capable of forming: (1) FGF2 and erythropoietin (EPO)-dependent large erythroid colonies; (2) FGF2, EPO and stem cell factor (SCF)-dependent mixed colonies composed of erythroid and megakaryocytic cells and macrophages; (3) FGF2 and IL3-dependent myeloid colonies; and (4) megakaryocytic colonies, which preferentially develop in cultures lacking EPO.

**Defining Hemangioblasts and Mesodermal Stage of Development in PSC Differentiation Cultures**

HBs are considered as multipotent progenitors with endothelial and hematopoietic potential. HBs were defined by Murray as CD235a+CD43lowCD41a− phenotype, had unique functional properties (see Table 1). They were capable of forming a broad spectrum of hematopoietic colonies in serum-free clonogenic medium containing FGF2 and hematopoietic cytokines, but not in serum-containing CFC medium. Interestingly, they also retained endothelial potential. Because VE-cadherin+CD73+CD43lowCD41a− cells have primary hematopoietic CFC potential and phenotype, we designated these cells as angiogenic hematopoietic progenitors (AHP) rather than HEPs. This designation was also supported by molecular profiling data that revealed the lack of critical endothelial gene expression such as CLDN5, CAV1, APOLD1, EMCN and SOX17 by AHPs (Fig. 2B).

Although AHPs expressed erythroid markers, they formed erythroid, myeloid and mixed colonies, indicating that they are multipotent hematopoietic cells, which include CFCs capable of forming: (1) FGF2 and erythropoietin (EPO)-dependent large erythroid colonies; (2) FGF2, EPO and stem cell factor (SCF)-dependent mixed colonies composed of erythroid and megakaryocytic cells and macrophages; (3) FGF2 and IL3-dependent myeloid colonies; and (4) megakaryocytic colonies, which preferentially develop in cultures lacking EPO.

**Table 1. Phenotypic and functional properties of angiohematopoietic and hematopoietic progenitors from hPSCs**

| Abbreviation and phenotype | Day | Definition | Endothelial potential | BL-CFC potential | Blood formation on OP9 | Hematopoietic CFCs potential |
|---------------------------|-----|-----------|-----------------------|------------------|-----------------------|-----------------------------|
| PM | 3   | Primitive posterior mesoderm enriched in cells expressing typical primitive streak and lateral plate/extraembryonic mesoderm genes | + | + | + | − | − |
| HVMP | 4   | Hematovascular mesodermal precursor expressing genes associated with lateral plate/extraembryonic mesoderm and angiohematopoietic commitment, but lacking the expression of primitive streak genes | + | − | + | − | − |
| HEP | 5   | Hemogenic endothelial progenitors | + | − | + | − | − |
| non-HEP | 5   | Non-hemogenic endothelial progenitors | + | − | − | − | − |
| AHP | 5   | Angiogenic hematopoietic progenitors | + | − | NA | +++ | Limited |
| EMkP | 5–8 | Erythromegakaryocytic progenitors | − | − | NA | ++ | Limited |
| MHP | 7–8 | Multipotential hematopoietic progenitors that lack expression of hematopoietic lineage-specific hematopoietic markers (lin−) | − | − | NA | NT | +++ |

PM: Primitive posterior mesoderm enriched in cells expressing typical primitive streak and lateral plate/extraembryonic mesoderm genes

HVMP: Hematovascular mesodermal precursor expressing genes associated with lateral plate/extraembryonic mesoderm and angiohematopoietic commitment, but lacking the expression of primitive streak genes

HEP: Hemogenic endothelial progenitors

non-HEP: Non-hemogenic endothelial progenitors

AHP: Angiogenic hematopoietic progenitors

EMkP: Erythromegakaryocytic progenitors

MHP: Multipotential hematopoietic progenitors that lack expression of hematopoietic lineage-specific hematopoietic markers

lin−, lack of the expression of CD31, VE-cadherin endothelial, CD73 and CD105 mesenchymal/endothelial cell markers CD43 and CD45 hematopoietic cell markers; lin−, lack of the expression of mature blood lineages markers; SF, serum-free; HC, hematopoietic cytokines; NA, not applicable; NT, not tested. Day indicates the day of differentiation at which progenitors are detected.
yolk sac mesenchyme (mesoderm) aggregates from which endothelial and blood cells develop. However, in modern literature, the term “hemangioblast” is applied very broadly to describe any type of embryonic or adult cells with endothelial and hematopoietic potentials, including hemogenic endothelium. After the discovery of BL-CFCs by the Keller group, the term “hemangioblast” has come to be used for bipotential cells generated within the posterior primitive streak in the mouse embryo or its equivalent during ESC differentiation. The broad definition of HBs often lead to confusion regarding the type of cells studied and make it difficult to discriminate between the distinct stages of angiohematopoietic development during hPSC differentiation. For example, multiple cell populations identified in our studies have both endothelial and hematopoietic potential, and therefore could be defined as HBs. Therefore, we suggest to limit the use of the term “hemangioblast” to describe multipotential mesodermal rather than endothelial cells, as originally proposed by Murray. During hPSC differentiation, mesoderm can be defined as a stage of development when cells express the mesodermal marker, APLNR, but lack the expression of typical endothelial, mesenchymal and hematopoietic markers (EMHlin− cells; Fig. 1). Since BL-CFCs represent the best-characterized clonalogenic mesodermal cells, with endothelial and hematopoietic potentials, and have a defined in vivo equivalent, it would be wise to further restrict the use of the term “hemangioblast” to mesoderm with BL-CFC potential, as originally described by the Keller group. As we showed, the potential to form BL colonies in serum-free medium in response to FGF2 discriminates PM from more mature mesodermal cells (HVMPs), which are also capable of generating blood and endothelial cells, but require serum and hematopoietic cytokines for differentiation.

We identified FGF2 as the most critical factor required for HB development in vitro, which is consistent with in vivo studies demonstrating the essential role of FGF2 in HB induction. Interestingly, the sequence of events leading to HB-colony development in vitro highly resembles the events observed in vivo during embryonic differentiation.

**Figure 2.** Characterization of hPSC-derived angiohematopoietic progenitors. (A) Heat maps of selected genes to demonstrate the key transcriptional features of PM and HVMPs. LP/EE M is lateral plate/extraembryonic mesoderm. PS is posterior streak. (B) Heat maps of selected genes to demonstrate the key transcriptional features of HEPs and non-HEPs. Outlined yellow box emphasizes the most critical genes differentially expressed in HEPs and non-HEPs. EC p2 is second passage of endothelial cells obtained from day 8 CD31+CD43− differentiated H1 hESCs. HUVEC human umbilical vein endothelial cells. See Table 1 for other abbreviations. The gene expression levels are estimated in terms of “transcripts per million.” (C) Formation of hematoendothelial clusters by HVMPs on OP9. Immunofluorescent staining with VE-cadherin and CD43 antibodies is shown.
development. In the chicken embryo, activation of FGF-signaling leads to the aggregation of migrating mesodermal cells adjacent to the endoderm, upregulation of VEGFR2 (KDR) expression and subsequent formation of angioblasts and hemangioblasts. Similar to our in vitro studies demonstrated that PM cells display high motility when placed in FGF2-containing clonogenic medium. In response to FGF2, PM cells undergo several divisions, upregulate expression of KDR and other endothelial genes, including CDH5, PECAM and ESAM, and form motile tight aggregates composed of approximately 30 VE-cadherin+ epithelioid cells (cores). Subsequently, VE-cadherin+ core-forming epithelioid cells undergo endothelial-to-hematopoietic transition, giving rise to CD235a+CD41a+ primitive blood cells. Although our and other studies demonstrated that BL-CFCs (HBs) produce mostly primitive hematopoietic cells, the possibility that HBs have definitive hematopoietic potential cannot be entirely excluded. It is possible that BL-CFCs have both primitive and definitive hematopoietic potential, but our culture conditions used for HB detection selectively support development of primitive hematopoietic cells and inhibit HBs maturation into definitive hematopoietic cells. In order to test this hypothesis, we would need to isolate BL-CFCs and culture them in conditions that support definitive hematopoietic cell differentiation. Unfortunately, these studies can’t be performed at present time, since HB-specific markers are currently unknown. Although selection of APLNR+ or KDR+ cells from day 3 differentiated hESCs significantly enriches for BL-CFCs, the percentage of BL-CFCs within these populations remain a low 1.5–4%. The emerging VE-cadherin+ cells generated from PSCs represent endothelial progenitors, which should not be equated entirely with endothelial cells forming the lining of already established blood vessels in the embryo. During development, the earliest VE-cadherin+ cells are detected within the Flk1+ mesoderm in the extraembryonic region (the future yolk sac) of E6.75 gastrulating mouse embryo. Although these cells coexpress CD31, CD34, Tie2 and endoglin, they are considered as mesoderm, since they form masses of morphologically indistinguishable mesodermal cells rather than distinct vascular structures. The similar type of VE-cadherin+ cells was detected within visceral yolk sac mesoderm at later stages of development (E7.0–7.5). VE-cadherin+ cells at this location are bipotential and capable of generating primitive and definitive hematopoietic and endothelial cells. When the rudimentary intraembryonic circulatory system is established in the mouse between E8.0 and E8.5, VE-cadherin is detected in the endocardial primordia, definitive endocardium and aortic primordia (loosely associated cords of primordial endothelial cells formed by segregation from mesoderm at initial stages of vasculogenesis). These data indicate significant functional diversity of emerging VE-cadherin+ cells in the embryo. Similarly, our studies revealed that VE-cadherin+ cells generated from PSCs are phenotypically and functionally diverse. However, we consider all of them as angiogenic/endothelial progenitors, because all first emerging VE-cadherin+ populations express typical endothelial genes and possess endothelial potential. Following acquisition of VE-cadherin expression, cells become smaller compared with HVMPs and eventually acquire typical endothelial or hematopoietic morphology, indicative of maturation and terminal differentiation. The markers that discriminate VE-cadherin+ progenitors from mature endothelial cells remain largely unknown. Since vWF is not detected in emerging endothelial cells, but rather upregulated in endothelial cell cultures generated from early VE-cadherin+ cells (Fig. 2B), its expression may be helpful to discriminate immature and mature endothelial cells.

CD235a erythroid marker is detected within the earliest VE-cadherin+ cells, designated as AHPs. These cells have the capacity to form myeloid and erythroid colonies, which morphologically resemble BL-CFC (HBs) colonies. In addition, similar to HBs, AHPs possess endothelial potential and require FGF2 for colony formation. Because of these properties, they could easily be confused with HBs. However, in contrast to HBs, colony development from AHPs is hematopoietic cytokine-dependent and does not proceed through endothelial core stage. The in vivo equivalent of AHPs remains unclear. Because AHPs have broad erythroid and myeloid differentiation potential, they may represent a transient wave of definitive erythromyeloid hematopoiesis, similar to the one described in mouse yolk sac.

**Defining Endothelial Progenitor Stage in PSC Differentiation Cultures**

Since VE-cadherin plays essential role in maintaining of vascular integrity and is considered as one of the most specific marker for endothelial cells, we defined the beginning of endothelial lineage development in PSC differentiation cultures by the upregulation of VE-cadherin. The emerging VE-cadherin+ cells generated from PSCs represent endothelial progenitors, which should not be equated entirely with endothelial cells forming the lining of already established blood vessels in the embryo. During development, the earliest VE-cadherin+ cells are detected within the Flk1+ mesoderm in the extraembryonic region (the future yolk sac) of E6.75 gastrulating mouse embryo. Although these cells coexpress CD31, CD34, Tie2 and endoglin, they are considered as mesoderm, since they form masses of morphologically indistinguishable mesodermal cells rather than distinct vascular structures. The similar type of VE-cadherin+ cells was detected within visceral yolk sac mesoderm at later stages of development (E7.0–7.5). VE-cadherin+ cells at this location are bipotential and capable of generating primitive and definitive hematopoietic and endothelial cells. When the rudimentary intraembryonic circulatory system is established in the mouse between E8.0 and E8.5, VE-cadherin is detected in the endocardial primordia, definitive endocardium and aortic primordia (loosely associated cords of primordial endothelial cells formed by segregation from mesoderm at initial stages of vasculogenesis). These data indicate significant functional diversity of emerging VE-cadherin+ cells in the embryo. Similarly, our studies revealed that VE-cadherin+ cells generated from PSCs are phenotypically and functionally diverse. However, we consider all of them as angiogenic/endothelial progenitors, because all first emerging VE-cadherin+ populations express typical endothelial genes and possess endothelial potential. Following acquisition of VE-cadherin expression, cells become smaller compared with HVMPs and eventually acquire typical endothelial or hematopoietic morphology, indicative of maturation and terminal differentiation. The markers that discriminate VE-cadherin+ progenitors from mature endothelial cells remain largely unknown. Since vWF is not detected in emerging endothelial cells, but rather upregulated in endothelial cell cultures generated from early VE-cadherin+ cells (Fig. 2B), its expression may be helpful to discriminate immature and mature endothelial cells.

**Hemogenic Endothelium as a Platform for the Study HSC Development In Vitro**

Identifying immediate precursors of blood cells from differentiating hPSCs will be critical to model blood development in vitro. This system especially provides an opportunity to identify the factors required for blood cells to acquire self-renewing potential, i.e., HSC properties, as they emerge from endothelium. Recently, other groups have demonstrated the endothelial origin of blood cells during hPSCs differentiation. Using hESCs engineered to express fluorescent reporters under VE-cadherin or CD41a promoter, the James group was able to directly observe the formation of round blood cells from VE-cadherin+ epithelioid precursors. The Keller group demonstrated that CD43+ cells expressing endothelial marker can be differentiated into T cells, indicating that HE generated in vitro are multipotent and have lymphoid potential. However, it remains to be determined whether we can recapitulate somatic HSC specification from HE in vitro as it occurs in vivo. Several studies have reported hematopoietic engraftment from hESC- and iPSC-derived hematopoietic cells. Although human cells were detected in the recipient bone marrow 3–6 mo after transplantation of differentiated hESCs to immunocompromised mice, the engraftment rate was very low.
and mostly restricted to the myeloid lineage. In the mouse system, development of HSCs with robust engraftment potential from mESCs requires the overexpression of Hoxb4 or Cdx4 genes to specify ESC-derived cells toward HSC fate. Several groups engineered human ESCs to overexpress Hoxb4. However, hematopoietic cells generated from these cell lines failed to engraft. Because specification of mouse ESCs to HSCs can be achieved only within particular differentiation window (the stage at which CD41a `c-kit' cells emerge), it is possible that HOXB4-sensitive window and stage of differentiation was missed and/or not appropriately targeted in human cells. It is also possible that species-specific differences exist between human and mouse ESCs. Our molecular profiling studies demonstrated that hESC-derived hematopoietic progenitors already express a high level of HOX cluster genes, while HOXA cluster genes are significantly reduced as compared with phenotypically similar hematopoietic cells from fetal liver. Therefore, different HOX genes in humans may be required for specification of primitive hematopoietic cells toward definitive HSCs. It should be noted that Hoxb4-induced HSCs from mouse ESCs are not entirely similar to somatic HSCs. ESC-HSCs lack HoxA9 expression and transcriptional response to Notch signaling. Hematopoiesis from these cells is skewed toward the myeloid lineage, indicating that Hoxb4-induced cells are not completely transformed into somatic HSC-like cells. Further studies are needed to determine the factors necessary to complete the somatic HSC program in the developing hematopoietic cells from in vitro-generated HE.

In conclusion, identification of HEPs and distinct stages of angiohematopoietic development from hPSCs in our studies establishes a platform for further investigation of stage-specific molecular pathways required for the specification and expansion of HSCs from hPSCs.

Disclosure of Potential Conflicts of Interest I.S. is a founder, stock owner, and consultant of Cellular Dynamics International (CDI). I.S. is also a founder, stock owner and serves on the Board of Directors of Cynata.

Acknowledgments

I thank Gene Uenishi for editorial assistance. This work was supported by funds from the National Institute of Health (R01 HL081962, U01 HL099773) and the Charlotte Geyer Foundation.

References

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145-7; PMID:9685456; http://dx.doi.org/10.1126/science.282.5391.1145
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-72; PMID:17985408; http://dx.doi.org/10.1016/j.cell.2007.11.019
3. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell line derived from human somatic cells. Science 2007; 318:1917-20; PMID:18029452; http://dx.doi.org/10.1126/science.1151526
4. Timmermans F, Velge I, Vanwaes L, De Smedt M, Van Coillie E, Taghon T, et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J Immunol 2009; 182:6879-89; PMID:19454684; http://dx.doi.org/10.4049/jimmunol.0800670
5. Wall PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol 2005; 175:5095-103; PMID:16201603
6. Lu SJ, Feng Q, Park JS, Lee BS, Strausbauch L, Scott E, et al. Induction of pigmented retina in human ES cells. Nature 2008; 453:148-53; PMID:18278347; http://dx.doi.org/10.1038/nature06987
7. Ross JL, Varga Z, Yang Y, et al. Fate tracing reveals the endothelial potential, probed before circulation in mouse. Cell Stem Cell 2010; 7:718-29; PMID:21112566; http://dx.doi.org/10.1016/j.stem.2010.11.011
8. Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 1996; 86:897-906; PMID:8808625; http://dx.doi.org/10.1016/S0092-8674(00)81865-8
9. de Brujin MF, Ma X, Robin C, Ottersbach K, Sanchez MI, Dzierzak E. Hematopoietic stem cells localize to the endothelial cell layer in the midgestation mouse aorta. Immunity 2002; 16:673-83; PMID:12049719; http://dx.doi.org/10.1016/S1074-7613(02)00315-8
10. Camano A, Dietzler-Lievere F, Godin I. Lymphoid potential, probe before circulation in mouse, is restricted to caudal intraembryonic splanchopleura. Cell 1996; 86:907-16; PMID:8808626; http://dx.doi.org/10.1016/S0092-8674(00)81866-X
11. Zovein AC, Hofmann JF, Lynch M, French WJ, Turlo KA, Yang Y, et al. Fate tracing reveals the endothelial origin of hematopoietic stem cells. Cell Stem Cell 2008; 3:625-36; PMID:19044779; http://dx.doi.org/10.1016/j.stem.2008.09.018
12. Jaffredo T, Gautier R, Breaud V, Dietzler-Lievere F. Tracing the progeny of the aortic hemangioblast in the avian embryo. Dev Biol 2000; 224:204-14; PMID:1092670; http://dx.doi.org/10.1006/dbio.2000.7979
13. Dantschkofski V. Uber das eraten auftreten der blutele -ments in huhnerembryo. Folia Haematologica 1907; 415-66
14. Boisset JC, van Cappellen W, Andrieu-Soler C, Gallart N, Dzierzak E, Robin C. In vivo imaging of hematopoietic cells emerging from the mouse aortic endothelium. Nature 2010; 464:116-20; PMID:20154729; http://dx.doi.org/10.1038/nature08764
15. Kissa K, Herbolom P. Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature 2010; 464:112-5; PMID:20154732; http://dx.doi.org/10.1038/nature08783
16. Bertrand JY, Chi NC, Santoso B, Teng S, Stainier DY, Traver D. Haematopoietic stem cells derive directly from aortic endothelium during development. Nature 2010; 464:108-11; PMID:20154733; http://dx.doi.org/10.1038/nature08783
17. Yokomizo T, Dietzler E. Three-dimensional cartography of hematopoietic clusters in the vasculature of whole mouse embryos. Development 2010; 137:3651-61; PMID:20876651; http://dx.doi.org/10.1242/dev.031094
18. Gezas C, Dietzler-Lievere F, Orkin SH, Mikkel HK, the placenta is a niche for hematopoietic stem cells. Dev Cell 2005; 3:835-75; PMID:15737992; http://dx.doi.org/10.1016/j.devcel.2004.12.016
19. Li Z, Lan Y, He W, Chen D, Wang J, Zhou F, et al. Mouse embryonic head as a source for hematopoietic stem cell development. Cell Stem Cell 2012; 11:663-75; PMID:23122290; http://dx.doi.org/10.1016/j.jif.2012.07.004
20. Li W, Ferkowicz MJ, Johnson SA, Shelley WC, Yoder MC. Endothelial cells in the early murine yolk sac give rise to CD45-expressing hematopoietic cells. Stem Cells Dev 2005; 14:44-54; PMID:15725743; http://dx.doi.org/10.1089/scd.2005.14.44
21. Vodyanik MA, Boek JA, Thomson JA, Slukvin II. Human embryonic stem cell-derived CD34+ cells: efficient production in the co-culture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 2005; 105:617-26; PMID:15374881; http://dx.doi.org/10.1182/blood-2004-04-1649
22. Li ZY, Yu J, Yang Y, et al. Mesenchymal cell-derived hematopoietic progenitors. Stem Cells Dev 2009; 18:1273-83; PMID:1929936
23. Vodyanik MA, Yu J, Zhang X, Tian S, Stewart R, Thomson JA, et al. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 2010; 7:718-29; PMID:21112566; http://dx.doi.org/10.1016/j.stem.2010.11.011
32. D’Aniello C, Lonardo E, Iaconis S, Guardiola O, Lago AM, Liguori G, et al. Expression of FGF receptor alpha, e-kit and fkh1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. Development 1999; 126:729-39; PMID:9943833; http://dx.doi.org/10.1242/dev.1999.00009.x

33. Yoda Y, Nishimura T, Ogaeri T, Takeuchi Y, Nishimura K, et al. Progenitor analysis of hematopoietic cells generated from human embryonic stem cells. Blood 2012; 119:6243-54; PMID:22611158; http://dx.doi.org/10.1182/blood-2011-12-396093

34. Shalaby F, H Jo, Stanford WL, Fischer KD, Schuh AC, Schwartz L, et al. Requirement for Fkh1 in progenitor and terminal hematopoiesis and vasculogenesis. Cell 1997; 89:981-90; PMID:9209616; http://dx.doi.org/10.1016/S0092-8674(00)82384-4

35. Kataoka H, Takakura N, Nishikawa S, Tsuchida K, Nakauchi H, et al. CD226 mediates platelet adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996; 4:573-81; PMID:8776688; http://dx.doi.org/10.1016/0898-6275(96)82334-2

36. Vodyanik MA, Thomson JA, Slukvin II. Leukosialin of Cripto to specify embryonic stem cells toward the hematopoietic and endothelial fates. Development 2003; 130:4217-27; PMID:12874193; http://dx.doi.org/10.1242/dev.005858

37. Choi KD, Vodyanik MA, Togarrati PP, Suknuntha R, Tachibana K, et al. Identification of the hemogenic endothelial progenitor and its direct precursor in human pluripotent stem cell differentiation cultures. Cell Rep 2012; 1:255-67; PMID:22981233; http://dx.doi.org/10.1016/j.celrep.2012.08.002

38. Kennedy M, Awong G, Sturgeon CM, Ditadi A, Leventhal AL, et al. Identification of definitive erythropoiesis and definitive hematopoietic progenitors in human embryonic stem cell differentiation cultures. Blood 2006; 108:2095-105; PMID:16757688; http://dx.doi.org/10.1182/blood-2006-02-003237

39. Choi KD, Vodyanik MA, Togarri PP, Suknuntha R, Tachibana K, et al. Identification of the hemogenic endothelial progenitor and its direct precursor in human pluripotent stem cell differentiation cultures. Cell Rep 2012; 1:255-67; PMID:22981233; http://dx.doi.org/10.1016/j.celrep.2012.08.002

40. Kennedy M, D’Souza SL, Lynch-Kattman M, Schlaeger TM, Traver D, et al. A requirement for Flk1 in vasculogenesis and hematopoiesis in vitro. Development 1999; 126:435-9; PMID:12866673

41. Flavell R, Nakauchi H. A common precursor for primitive and definitive hematopoiesis in vitro. Development 1992; 116:71-9; PMID:13805601; http://dx.doi.org/10.1242/dev.1992.0189

42. Flavell R, Ouadsir F, Glozelle L, et al. Characterization of nascent mesodermal cells. Dev Growth Differ 1995; 37:371-92; PMID:8875054; http://dx.doi.org/10.1182/blood-2005-08-1522

43. Leventhal AL, Kennedy M, Nakauchi H, et al. Hematopoietic and endothelial progenitor cells are capable of engrafting primary as well as secondary fetal sheep recipients. Blood 2006; 107:2180-3; PMID:16278307; http://dx.doi.org/10.1182/blood-2005-05-1922

44. Liedman MH, Krasowska A, Armstrong L, Dimnick I, Rensstrom J, Lang R, et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 2008; 3:85-98; PMID:18395361; http://dx.doi.org/10.1016/j.stem.2008.06.001

45. Lu M, Kardel MD, O’Connor MD, Eaves CJ. Enhanced generation of hematopoietic cells from human hematopoietic cell-stimulated human embryonic and induced pluripotent stem cells. Exp Hematol 2009; 37:924-38; PMID:19468115; http://dx.doi.org/10.1016/j.exphem.2009.05.007

46. Lyba M, Perleingue RC, Daley GQ. HOXB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002; 109:29-37; PMID:11855444; http://dx.doi.org/10.1016/S0092-8674(02)00680-3

47. Wang Y, Yates F, Naveiras O, Ernst P, Daley GQ. Embryonic stem cell-derived hematopoietic progenitors. Proc Natl Acad Sci USA 2005; 102:10390-1; PMID:16157205; http://dx.doi.org/10.1073/pnas.0506127102

48. Lee GS, Kim BS, Sheikh JH, Moore M. Forced expression of HOXB4 enhances hematopoietic differentiation of human embryonic stem cells. Mol Cells 2008; 25:487-93; PMID:18511880

49. Unger C, Kärner E, Treschow A, Stellarn B, Feldlin U, Concha H, et al. Lentiviral-mediated HOXB4 expression in human embryonic stem cells initiates early hematopoiesis in a dose-dependent manner but does not promote myeloid differentiation. Cell Stem Cell 2008; 2:2455-66; PMID:18617691; http://dx.doi.org/10.1016/j.stem.2007.08-0767

50. Matsumoto K, Isagawa T, Nishimura T, Ogaeri T, et al. Progenitor analysis of hematopoietic cells generated from human embryonic stem cells. Biochem Biophys Res Commun 2009; 379:587-92; PMID:19484891; http://dx.doi.org/10.1016/j.bbrc.2009.06.037

51. Drake CJ, Fleming PA. Vasculogenesis in the developing heart. Blood 2000; 95:1671-9; PMID:10688823

52. McGrath KE, Frame JM, Fromm G, Konisky AD, Kingsley PD, Little J, et al. A transient definitive erythroid lineage forms through unique regulation of the β-globin locus in the mammalian embryo. Blood 2011; 117:4600-8; PMID:21378272; http://dx.doi.org/10.1182/blood-2010-12-325357

53. Raff S, Kloss CC, Butler JM, Ginsberg M, Gars E, Liu B, et al. Hematopoietic and endothelial cells undergo distinct, staggered waves of endothelial commitment during hematopoietic differentiation. Blood 2013; 121:770-80; PMID:23569780

54. Kennedy M, Arredondo G, Sturgeon CM, Ditadi A, Lamorte-Mai M, Zúñiga-Pflucker JC, et al. Erythroid differentiation of human hematopoietic progenitors in human pluripotent stem cell differentiation cultures. Cell Rep 2012; 1:2572-35; PMID:23258360; http://dx.doi.org/10.1016/j.celrep.2012.11.003

55. Wang L, Menendez P, Shojaei F, Li L, Mazurier F, Dick JE, et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOX84 expression. J Exp Med 2005; 201:1603-14; PMID:15883170; http://dx.doi.org/10.1084/jem.20041888

56. Kaufman DS, Woll PHC, Martin JL, Xinghui TL. CD34+ Cells Derived from Human Embryonic Stem Cells Demonstrate Hematopoietic Stem Cell Potential In Vitro and In Vivo. Blood 2004; 104:165a

57. Narayan AD, Chase JL, Lewis RL, Tian X, Kaufman DS, Thomson JA. Human embryonic stem cell-derived hematopoietic cells are capable of engrafting primary as well as secondary fetal sheep recipients. Blood 2006; 107:2180-3; PMID:16278307; http://dx.doi.org/10.1182/blood-2005-05-1922

58. McInnis-McKee F, Hamin E, Lang R, et al. The transcriptional landscape of hematopoietic stem cell ontology. Cell Stem Cell 2012; 11:701-14; PMID:23122293; http://dx.doi.org/10.1016/j.stem.2012.07.018

www.landesbioscience.com Cell Cycle 727